Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Latest preclinical studies reveal significant improvements in stability, efficacy, and KRAS targeting range for next-generation siRNA candidate SIL-204 Silexion Therapeutics Corp. (NASDAQ: SLXN...
New analysis from Silexion's Phase 2 trial of LODER shows a 56% objective response rate (ORR) and 67% resectability improvement in non-resectable pancreatic cancer Silexion Therapeutics Corp...
Report covers Silexion Therapeutics (NASDAQ: SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the...
RUNNEMEDE, N.J., Aug. 15 /PRNewswire-FirstCall/ -- Sielox, Inc. (OTC:SLXN) (BULLETIN BOARD: SLXN) , a developer, designer and distributor of security solution and industrial vision products...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1225 | -19.6787148594 | 0.6225 | 0.721 | 0.5 | 12574513 | 0.55886712 | CS |
| 4 | -0.6 | -54.5454545455 | 1.1 | 1.4 | 0.5 | 6255924 | 0.78740317 | CS |
| 12 | -4.07 | -89.0590809628 | 4.57 | 4.65 | 0.5 | 4430018 | 0.89957457 | CS |
| 26 | -4.07 | -89.0590809628 | 4.57 | 4.65 | 0.5 | 4430018 | 0.89957457 | CS |
| 52 | -4.07 | -89.0590809628 | 4.57 | 4.65 | 0.5 | 4430018 | 0.89957457 | CS |
| 156 | -4.07 | -89.0590809628 | 4.57 | 4.65 | 0.5 | 4430018 | 0.89957457 | CS |
| 260 | -4.07 | -89.0590809628 | 4.57 | 4.65 | 0.5 | 4430018 | 0.89957457 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
